Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment (NCT05213598) | Clinical Trial Compass
RecruitingNot Applicable
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
United States100 participantsStarted 2022-09-07
Plain-language summary
Background:
In Fontan Associated Liver Disease (FALD), congestion of blood in the liver causes cirrhosis. This condition can cause death. Researchers want to understand what triggers this process and find new treatments for it.
Objective:
To understand how long-term congestion of blood in the liver causes liver scarring that eventually leads to cirrhosis.
Eligibility:
People aged 18 and older who are at risk of developing FALD from the Fontan procedure.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Liver ultrasound. This uses sound waves to take pictures of the body.
Participants will have an outpatient visit within 12 weeks after screening. Within 24 weeks later, they will have a 3-day hospital stay. About 2 weeks later, they will have a follow-up visit.
Visits will include repeats of the screening tests and:
Heart tests
Stool collection
Questionnaires
MRI of the liver. Participants will lie on a bed that slides in and out of the scanner. They will receive a contrast agent injected into a vein. While in the scanner, they will also have an MRCP to view the bile ducts and the pancreatic duct.
Fibroscan exam. This is an ultrasound that uses a special probe to look at the toughness of the liver.
Upper endoscopy. This uses a thin scope to look inside the upper digestive tract.
Liver biopsy. This will be taken through large vein in the neck or through the chest. Just before the biopsy, participants will have pressure measurements inside their liver. For this, a catheter will be inserted into a neck vein and guided into the liver.
Who can participate
Age range18 Years – 100 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male and female subjects \>= 18 years of age.
✓. Past surgical history of Fontan procedure.
✓. Prior enrollment in the Liver Diseases Branch protocol 91DK0214
✓. Underwent cardiac catheterization or transjugular liver biopsy within ten years prior to the date of screening
✓. Approved to proceed by the NIH Cardiology Consult
✓. Approved to proceed by the NIH Cardiac Pre-anesthesia Consult
Exclusion criteria
✕. Evidence of other forms of liver disease that typically result in cirrhosis.
✕. Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (\>10,000 IU/mL).
✕. Hepatitis C as defined by the presence of hepatitis C RNA in serum.
✕
What they're measuring
1
To generate understanding of how congestive hepatopathy drives the pathogenesis of cirrhosis in FALD
Timeframe: End of Study
Trial details
NCT IDNCT05213598
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
. Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
✕. Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of \>45% and serum ferritin levels of \>300 ng/ml for men and \>250 ng/ml for women will undergo genetic testing for hemochromatosis.
✕. Bile duct obstruction as suggested by imaging studies done within the previous six months.
✕. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during patient interviews or by patient self-report).
✕. Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal \<6.6 ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.